PofoliaShared via Pofolia

Nutrients· 2020Q1

Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths

William B. Grant, Henry Lahore, Sharon L. McDonnell, Carole A. Baggerly et al.

Short summary

Vitamin D supplementation may reduce the risk of influenza and COVID-19 infections and deaths by enhancing innate immunity and reducing inflammation, with a proposed regimen of 10,000 IU/d for rapid increase followed by 5,000 IU/d to maintain levels above 40-60 ng/mL.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Vitamin D enhances innate immunity by inducing antimicrobial peptides (cathelicidins, defensins) that inhibit viral replication.
  • Vitamin D reduces pro-inflammatory cytokines, mitigating lung inflammation and injury associated with respiratory infections.
  • Observational data and trial results suggest vitamin D supplementation reduces influenza risk.
  • COVID-19 risk and severity correlate with lower vitamin D levels, seasonal patterns, and chronic disease comorbidities.
  • A proposed supplementation regimen is 10,000 IU/d for several weeks, followed by 5,000 IU/d, to reach 25(OH)D concentrations above 40-60 ng/mL.

AI-generated from the title and abstract; the full text is not read.

Abstract

The world is in the grip of the COVID-19 pandemic. Public health measures that can reduce the risk of infection and death in addition to quarantines are desperately needed. This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk. Through several mechanisms, vitamin D can reduce risk of infections. Those mechanisms include inducing cathelicidins and defensins that can lower viral replication rates and reducing concentrations of pro-inflammatory cytokines that produce the inflammation that injures the lining of the lungs, leading to pneumonia, as well as increasing concentrations of anti-inflammatory cytokines. Several observational studies and clinical trials reported that vitamin D supplementation reduced the risk of influenza, whereas others did not. Evidence supporting the role of vitamin D in reducing risk of COVID-19 includes that the outbreak occurred in winter, a time when 25-hydroxyvitamin D (25(OH)D) concentrations are lowest; that the number of cases in the Southern Hemisphere near the end of summer are low; that vitamin D deficiency has been found to contribute to acute respiratory distress syndrome; and that case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 25(OH)D concentration. To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40–60 ng/mL (100–150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations.

The authors' abstract, as published at the source. Nutrients, 2020 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine